1. Rengo, Giuseppe, Lymperopoulos, Anastasios, Leosco, Dario, Koch, Walter J. 2010. GRK2 as a novel gene therapy target in heart failure. In Journal of molecular and cellular cardiology, 50, 785-92. doi:10.1016/j.yjmcc.2010.08.014. https://pubmed.ncbi.nlm.nih.gov/20800067/
2. Liu, Fuze, Huang, Yue, Liu, Fuhui, Wang, Hai. 2023. Identification of immune-related genes in diagnosing atherosclerosis with rheumatoid arthritis through bioinformatics analysis and machine learning. In Frontiers in immunology, 14, 1126647. doi:10.3389/fimmu.2023.1126647. https://pubmed.ncbi.nlm.nih.gov/36969166/
3. Reinkober, J, Tscheschner, H, Pleger, S T, Koch, W J, Raake, P W J. 2012. Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade. In Gene therapy, 19, 686-93. doi:10.1038/gt.2012.9. https://pubmed.ncbi.nlm.nih.gov/22336718/
4. Guo, Paipai, Jiang, Ji, Chu, Rui, Zhang, Shihao, Wang, Qingtong. 2023. GRK2 mediated degradation of SAV1 initiates hyperplasia of fibroblast-like synoviocytes in rheumatoid arthritis. In Acta pharmaceutica Sinica. B, 14, 1222-1240. doi:10.1016/j.apsb.2023.12.007. https://pubmed.ncbi.nlm.nih.gov/38486990/
5. Cannavo, Alessandro, Komici, Klara, Bencivenga, Leonardo, Ferrara, Nicola, Rengo, Giuseppe. 2017. GRK2 as a therapeutic target for heart failure. In Expert opinion on therapeutic targets, 22, 75-83. doi:10.1080/14728222.2018.1406925. https://pubmed.ncbi.nlm.nih.gov/29166798/
6. Thapaliya, Monica, Amponnawarat, Aetas, Tesmer, John J G, Ali, Hydar. 2022. GRK2 inhibitors, paroxetine and CCG258747, attenuate IgE-mediated anaphylaxis but activate mast cells via MRGPRX2 and MRGPRB2. In Frontiers in immunology, 13, 1032497. doi:10.3389/fimmu.2022.1032497. https://pubmed.ncbi.nlm.nih.gov/36275707/
智鼠故事 
